Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 13 entries
Sorted by: Best Match Show Resources per page
The role of PCNA as a scaffold protein in cellular signaling is functionally conserved between yeast and humans.

FEBS open bio

Olaisen C, Kvitvang HFN, Lee S, Almaas E, Bruheim P, Drabløs F, Otterlei M.
PMID: 29988559
FEBS Open Bio. 2018 May 31;8(7):1135-1145. doi: 10.1002/2211-5463.12442. eCollection 2018 Jul.

Proliferating cell nuclear antigen (PCNA), a member of the highly conserved DNA sliding clamp family, is an essential protein for cellular processes including DNA replication and repair. A large number of proteins from higher eukaryotes contain one of two...

Cite
Olaisen C, Kvitvang HFN, Lee S, et al. The role of PCNA as a scaffold protein in cellular signaling is functionally conserved between yeast and humans. FEBS Open Bio. 2018;8(7):1135-1145doi: 10.1002/2211-5463.12442.
Olaisen, C., Kvitvang, H. F. N., Lee, S., Almaas, E., Bruheim, P., Drabløs, F., & Otterlei, M. (2018). The role of PCNA as a scaffold protein in cellular signaling is functionally conserved between yeast and humans. FEBS open bio, 8(7), 1135-1145. https://doi.org/10.1002/2211-5463.12442
Olaisen, Camilla, et al. "The role of PCNA as a scaffold protein in cellular signaling is functionally conserved between yeast and humans." FEBS open bio vol. 8,7 (2018): 1135-1145. doi: https://doi.org/10.1002/2211-5463.12442
Olaisen C, Kvitvang HFN, Lee S, Almaas E, Bruheim P, Drabløs F, Otterlei M. The role of PCNA as a scaffold protein in cellular signaling is functionally conserved between yeast and humans. FEBS Open Bio. 2018 May 31;8(7):1135-1145. doi: 10.1002/2211-5463.12442. eCollection 2018 Jul. PMID: 29988559; PMCID: PMC6026702.
Copy Download .nbib Format: NLM
Broad-Spectrum Antibacterial Peptide Kills Extracellular and Intracellular Bacteria Without Affecting Epithelialization.

Frontiers in microbiology

Nepal A, Ræder SB, Søgaard CK, Haugan MS, Otterlei M.
PMID: 34899646
Front Microbiol. 2021 Nov 26;12:764451. doi: 10.3389/fmicb.2021.764451. eCollection 2021.

New antibacterial drugs with novel modes of action are urgently needed as antibiotic resistance in bacteria is increasing and spreading throughout the world. In this study, we aimed to explore the possibility of using APIM-peptides targeting the bacterial β-clamp...

Cite
Nepal A, Ræder SB, Søgaard CK, et al. Broad-Spectrum Antibacterial Peptide Kills Extracellular and Intracellular Bacteria Without Affecting Epithelialization. Front Microbiol. 2021;12:764451doi: 10.3389/fmicb.2021.764451.
Nepal, A., Ræder, S. B., Søgaard, C. K., Haugan, M. S., & Otterlei, M. (2021). Broad-Spectrum Antibacterial Peptide Kills Extracellular and Intracellular Bacteria Without Affecting Epithelialization. Frontiers in microbiology, 12764451. https://doi.org/10.3389/fmicb.2021.764451
Nepal, Anala, et al. "Broad-Spectrum Antibacterial Peptide Kills Extracellular and Intracellular Bacteria Without Affecting Epithelialization." Frontiers in microbiology vol. 12 (2021): 764451. doi: https://doi.org/10.3389/fmicb.2021.764451
Nepal A, Ræder SB, Søgaard CK, Haugan MS, Otterlei M. Broad-Spectrum Antibacterial Peptide Kills Extracellular and Intracellular Bacteria Without Affecting Epithelialization. Front Microbiol. 2021 Nov 26;12:764451. doi: 10.3389/fmicb.2021.764451. eCollection 2021. PMID: 34899646; PMCID: PMC8661032.
Copy Download .nbib Format: NLM
Targeting the non-canonical roles of PCNA modifies and increases the response to targeted anti-cancer therapy.

Oncotarget

Søgaard CK, Nepal A, Petrovic V, Sharma A, Liabakk NB, Steigedal TS, Otterlei M.
PMID: 31921382
Oncotarget. 2019 Dec 31;10(68):7185-7197. doi: 10.18632/oncotarget.27267. eCollection 2019 Dec 31.

Receptor tyrosine kinases (RTKs), such as HER2 and/or EGFR are important therapeutic targets in multiple cancer cells. Low and/or short response to targeted therapies are often due to activation of compensatory signaling pathways, and therefore a combination of kinase...

Cite
Søgaard CK, Nepal A, Petrovic V, et al. Targeting the non-canonical roles of PCNA modifies and increases the response to targeted anti-cancer therapy. Oncotarget. 2019;10(68):7185-7197doi: 10.18632/oncotarget.27267.
Søgaard, C. K., Nepal, A., Petrovic, V., Sharma, A., Liabakk, N. B., Steigedal, T. S., & Otterlei, M. (2019). Targeting the non-canonical roles of PCNA modifies and increases the response to targeted anti-cancer therapy. Oncotarget, 10(68), 7185-7197. https://doi.org/10.18632/oncotarget.27267
Søgaard, Caroline K, et al. "Targeting the non-canonical roles of PCNA modifies and increases the response to targeted anti-cancer therapy." Oncotarget vol. 10,68 (2019): 7185-7197. doi: https://doi.org/10.18632/oncotarget.27267
Søgaard CK, Nepal A, Petrovic V, Sharma A, Liabakk NB, Steigedal TS, Otterlei M. Targeting the non-canonical roles of PCNA modifies and increases the response to targeted anti-cancer therapy. Oncotarget. 2019 Dec 31;10(68):7185-7197. doi: 10.18632/oncotarget.27267. eCollection 2019 Dec 31. PMID: 31921382; PMCID: PMC6944453.
Copy Download .nbib Format: NLM
Differentially Expressed Extracellular Vesicle-Contained microRNAs before and after Transurethral Resection of Bladder Tumors.

Current issues in molecular biology

Strømme O, Heck KA, Brede G, Lindholm HT, Otterlei M, Arum CJ.
PMID: 34199766
Curr Issues Mol Biol. 2021 Jun 04;43(1):286-300. doi: 10.3390/cimb43010024.

Bladder cancer (BC) is currently diagnosed and monitored by cystoscopy, a costly and invasive procedure. Potential biomarkers in urine, blood, and, more recently, extracellular vesicles (EVs), have been explored as non-invasive alternatives for diagnosis and surveillance of BC. EVs...

Cite
Strømme O, Heck KA, Brede G, et al. Differentially Expressed Extracellular Vesicle-Contained microRNAs before and after Transurethral Resection of Bladder Tumors. Curr Issues Mol Biol. 2021;43(1):286-300doi: 10.3390/cimb43010024.
Strømme, O., Heck, K. A., Brede, G., Lindholm, H. T., Otterlei, M., & Arum, C. J. (2021). Differentially Expressed Extracellular Vesicle-Contained microRNAs before and after Transurethral Resection of Bladder Tumors. Current issues in molecular biology, 43(1), 286-300. https://doi.org/10.3390/cimb43010024
Strømme, Olaf, et al. "Differentially Expressed Extracellular Vesicle-Contained microRNAs before and after Transurethral Resection of Bladder Tumors." Current issues in molecular biology vol. 43,1 (2021): 286-300. doi: https://doi.org/10.3390/cimb43010024
Strømme O, Heck KA, Brede G, Lindholm HT, Otterlei M, Arum CJ. Differentially Expressed Extracellular Vesicle-Contained microRNAs before and after Transurethral Resection of Bladder Tumors. Curr Issues Mol Biol. 2021 Jun 04;43(1):286-300. doi: 10.3390/cimb43010024. PMID: 34199766.
Copy Download .nbib Format: NLM
Broad-Spectrum Antibacterial Peptide Kills Extracellular and Intracellular Bacteria Without Affecting Epithelialization.

Frontiers in microbiology

Nepal A, Ræder SB, Søgaard CK, Haugan MS, Otterlei M.
PMID: 34899646
Front Microbiol. 2021 Nov 26;12:764451. doi: 10.3389/fmicb.2021.764451. eCollection 2021.

New antibacterial drugs with novel modes of action are urgently needed as antibiotic resistance in bacteria is increasing and spreading throughout the world. In this study, we aimed to explore the possibility of using APIM-peptides targeting the bacterial β-clamp...

Cite
Nepal A, Ræder SB, Søgaard CK, et al. Broad-Spectrum Antibacterial Peptide Kills Extracellular and Intracellular Bacteria Without Affecting Epithelialization. Front Microbiol. 2021;12:764451doi: 10.3389/fmicb.2021.764451.
Nepal, A., Ræder, S. B., Søgaard, C. K., Haugan, M. S., & Otterlei, M. (2021). Broad-Spectrum Antibacterial Peptide Kills Extracellular and Intracellular Bacteria Without Affecting Epithelialization. Frontiers in microbiology, 12764451. https://doi.org/10.3389/fmicb.2021.764451
Nepal, Anala, et al. "Broad-Spectrum Antibacterial Peptide Kills Extracellular and Intracellular Bacteria Without Affecting Epithelialization." Frontiers in microbiology vol. 12 (2021): 764451. doi: https://doi.org/10.3389/fmicb.2021.764451
Nepal A, Ræder SB, Søgaard CK, Haugan MS, Otterlei M. Broad-Spectrum Antibacterial Peptide Kills Extracellular and Intracellular Bacteria Without Affecting Epithelialization. Front Microbiol. 2021 Nov 26;12:764451. doi: 10.3389/fmicb.2021.764451. eCollection 2021. PMID: 34899646; PMCID: PMC8661032.
Copy Download .nbib Format: NLM
Activating the Cpx response induces tolerance to antisense PNA delivered by an arginine-rich peptide in .

Molecular therapy. Nucleic acids

Frimodt-Møller J, Koulouktsis A, Charbon G, Otterlei M, Nielsen PE, Løbner-Olesen A.
PMID: 34484867
Mol Ther Nucleic Acids. 2021 Jun 24;25:444-454. doi: 10.1016/j.omtn.2021.06.009. eCollection 2021 Sep 03.

Cell-penetrating peptides (CPPs) are increasingly used for cellular drug delivery in both pro- and eukaryotic cells, and oligoarginines have attracted special attention. How arginine-rich CPPs translocate across the cell envelope, particularly for prokaryotes, is still unknown. Arginine-rich CPPs efficiently...

Cite
Frimodt-Møller J, Koulouktsis A, Charbon G, et al. Activating the Cpx response induces tolerance to antisense PNA delivered by an arginine-rich peptide in . Mol Ther Nucleic Acids. 2021;25:444-454doi: 10.1016/j.omtn.2021.06.009.
Frimodt-Møller, J., Koulouktsis, A., Charbon, G., Otterlei, M., Nielsen, P. E., & Løbner-Olesen, A. (2021). Activating the Cpx response induces tolerance to antisense PNA delivered by an arginine-rich peptide in . Molecular therapy. Nucleic acids, 25444-454. https://doi.org/10.1016/j.omtn.2021.06.009
Frimodt-Møller, Jakob, et al. "Activating the Cpx response induces tolerance to antisense PNA delivered by an arginine-rich peptide in ." Molecular therapy. Nucleic acids vol. 25 (2021): 444-454. doi: https://doi.org/10.1016/j.omtn.2021.06.009
Frimodt-Møller J, Koulouktsis A, Charbon G, Otterlei M, Nielsen PE, Løbner-Olesen A. Activating the Cpx response induces tolerance to antisense PNA delivered by an arginine-rich peptide in . Mol Ther Nucleic Acids. 2021 Jun 24;25:444-454. doi: 10.1016/j.omtn.2021.06.009. eCollection 2021 Sep 03. PMID: 34484867; PMCID: PMC8403718.
Copy Download .nbib Format: NLM
"Two hits - one stone"; increased efficacy of cisplatin-based therapies by targeting PCNA's role in both DNA repair and cellular signaling.

Oncotarget

Søgaard CK, Blindheim A, Røst LM, Petrović V, Nepal A, Bachke S, Liabakk NB, Gederaas OA, Viset T, Arum CJ, Bruheim P, Otterlei M.
PMID: 30197755
Oncotarget. 2018 Aug 21;9(65):32448-32465. doi: 10.18632/oncotarget.25963. eCollection 2018 Aug 21.

Low response rate and rapid development of resistance against commonly used chemotherapeutic regimes demand new multi-targeting anti-cancer strategies. In this study, we target the stress-related roles of the scaffold protein PCNA with a cell-penetrating peptide containing the PCNA-interacting motif...

Cite
Søgaard CK, Blindheim A, Røst LM, et al. "Two hits - one stone"; increased efficacy of cisplatin-based therapies by targeting PCNA's role in both DNA repair and cellular signaling. Oncotarget. 2018;9(65):32448-32465doi: 10.18632/oncotarget.25963.
Søgaard, C. K., Blindheim, A., Røst, L. M., Petrović, V., Nepal, A., Bachke, S., Liabakk, N. B., Gederaas, O. A., Viset, T., Arum, C. J., Bruheim, P., & Otterlei, M. (2018). "Two hits - one stone"; increased efficacy of cisplatin-based therapies by targeting PCNA's role in both DNA repair and cellular signaling. Oncotarget, 9(65), 32448-32465. https://doi.org/10.18632/oncotarget.25963
Søgaard, Caroline Krogh, et al. ""Two hits - one stone"; increased efficacy of cisplatin-based therapies by targeting PCNA's role in both DNA repair and cellular signaling." Oncotarget vol. 9,65 (2018): 32448-32465. doi: https://doi.org/10.18632/oncotarget.25963
Søgaard CK, Blindheim A, Røst LM, Petrović V, Nepal A, Bachke S, Liabakk NB, Gederaas OA, Viset T, Arum CJ, Bruheim P, Otterlei M. "Two hits - one stone"; increased efficacy of cisplatin-based therapies by targeting PCNA's role in both DNA repair and cellular signaling. Oncotarget. 2018 Aug 21;9(65):32448-32465. doi: 10.18632/oncotarget.25963. eCollection 2018 Aug 21. PMID: 30197755; PMCID: PMC6126690.
Copy Download .nbib Format: NLM
Increased Anticancer Efficacy of Intravesical Mitomycin C Therapy when Combined with a PCNA Targeting Peptide.

Translational oncology

Gederaas OA, Søgaard CD, Viset T, Bachke S, Bruheim P, Arum CJ, Otterlei M.
PMID: 25500092
Transl Oncol. 2014 Dec;7(6):812-23. doi: 10.1016/j.tranon.2014.10.005.

Non-muscle-invasive bladder cancers (NMIBCs) are tumors confined to the mucosa or the mucosa/submucosa. An important challenge in treatment of NMIBC is both high recurrence and high progression rates. Consequently, more efficacious intravesical treatment regimes are in demand. Inhibition of...

Cite
Gederaas OA, Søgaard CD, Viset T, et al. Increased Anticancer Efficacy of Intravesical Mitomycin C Therapy when Combined with a PCNA Targeting Peptide. Transl Oncol. 2014;7(6):812-23doi: 10.1016/j.tranon.2014.10.005.
Gederaas, O. A., Søgaard, C. D., Viset, T., Bachke, S., Bruheim, P., Arum, C. J., & Otterlei, M. (2014). Increased Anticancer Efficacy of Intravesical Mitomycin C Therapy when Combined with a PCNA Targeting Peptide. Translational oncology, 7(6), 812-23. https://doi.org/10.1016/j.tranon.2014.10.005
Gederaas, Odrun A, et al. "Increased Anticancer Efficacy of Intravesical Mitomycin C Therapy when Combined with a PCNA Targeting Peptide." Translational oncology vol. 7,6 (2014): 812-23. doi: https://doi.org/10.1016/j.tranon.2014.10.005
Gederaas OA, Søgaard CD, Viset T, Bachke S, Bruheim P, Arum CJ, Otterlei M. Increased Anticancer Efficacy of Intravesical Mitomycin C Therapy when Combined with a PCNA Targeting Peptide. Transl Oncol. 2014 Dec;7(6):812-23. doi: 10.1016/j.tranon.2014.10.005. PMID: 25500092; PMCID: PMC4311026.
Copy Download .nbib Format: NLM
[Important questions about the list patient system not yet asked].

Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke

Otterlei B.
PMID: 12934153
Tidsskr Nor Laegeforen. 2003 Aug 14;123(15):2103-4.

No abstract available.

Cite
Otterlei B. Viktige spørsmål om fastlegeordningen ennå ikke stilt. [Important questions about the list patient system not yet asked]. Tidsskr Nor Laegeforen. 2003;123(15):2103-4
Otterlei, B. (2003). Viktige spørsmål om fastlegeordningen ennå ikke stilt. [Important questions about the list patient system not yet asked]. Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 123(15), 2103-4.
Otterlei, Bjørn. "Viktige spørsmål om fastlegeordningen ennå ikke stilt." [Important questions about the list patient system not yet asked]. Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke vol. 123,15 (2003): 2103-4.
Otterlei B. Viktige spørsmål om fastlegeordningen ennå ikke stilt. [Important questions about the list patient system not yet asked]. Tidsskr Nor Laegeforen. 2003 Aug 14;123(15):2103-4. Norwegian. PMID: 12934153.
Copy Download .nbib Format: NLM
APIM-peptide targeting PCNA improves the efficacy of docetaxel treatment in the TRAMP mouse model of prostate cancer.

Oncotarget

Søgaard CK, Moestue SA, Rye MB, Kim J, Nepal A, Liabakk NB, Bachke S, Bathen TF, Otterlei M, Hill DK.
PMID: 29545934
Oncotarget. 2018 Jan 27;9(14):11752-11766. doi: 10.18632/oncotarget.24357. eCollection 2018 Feb 20.

Docetaxel is the chemotherapeutic choice for metastatic hormone-refractory prostate cancer, however, it only marginally improves the survival rate. The purpose of the present study was to examine if a peptide targeting the cellular scaffold protein PCNA could improve docetaxel's...

Cite
Søgaard CK, Moestue SA, Rye MB, et al. APIM-peptide targeting PCNA improves the efficacy of docetaxel treatment in the TRAMP mouse model of prostate cancer. Oncotarget. 2018;9(14):11752-11766doi: 10.18632/oncotarget.24357.
Søgaard, C. K., Moestue, S. A., Rye, M. B., Kim, J., Nepal, A., Liabakk, N. B., Bachke, S., Bathen, T. F., Otterlei, M., & Hill, D. K. (2018). APIM-peptide targeting PCNA improves the efficacy of docetaxel treatment in the TRAMP mouse model of prostate cancer. Oncotarget, 9(14), 11752-11766. https://doi.org/10.18632/oncotarget.24357
Søgaard, Caroline K, et al. "APIM-peptide targeting PCNA improves the efficacy of docetaxel treatment in the TRAMP mouse model of prostate cancer." Oncotarget vol. 9,14 (2018): 11752-11766. doi: https://doi.org/10.18632/oncotarget.24357
Søgaard CK, Moestue SA, Rye MB, Kim J, Nepal A, Liabakk NB, Bachke S, Bathen TF, Otterlei M, Hill DK. APIM-peptide targeting PCNA improves the efficacy of docetaxel treatment in the TRAMP mouse model of prostate cancer. Oncotarget. 2018 Jan 27;9(14):11752-11766. doi: 10.18632/oncotarget.24357. eCollection 2018 Feb 20. PMID: 29545934; PMCID: PMC5837745.
Copy Download .nbib Format: NLM
Novel Peptides Targeting the β-Clamp Rapidly Kill Planktonic and Biofilm .

Frontiers in microbiology

Raeder SB, Sandbakken ET, Nepal A, Løseth K, Bergh K, Witsø E, Otterlei M.
PMID: 33815313
Front Microbiol. 2021 Mar 17;12:631557. doi: 10.3389/fmicb.2021.631557. eCollection 2021.

Antimicrobial resistance is an increasing threat to global health and challenges the way we treat infections. Peptides containing the PCNA interacting motif APIM (APIM-peptides) were recently shown to bind to the bacterial PCNA homolog, the beta (β)-clamp, and to...

Cite
Raeder SB, Sandbakken ET, Nepal A, et al. Novel Peptides Targeting the β-Clamp Rapidly Kill Planktonic and Biofilm . Front Microbiol. 2021;12:631557doi: 10.3389/fmicb.2021.631557.
Raeder, S. B., Sandbakken, E. T., Nepal, A., Løseth, K., Bergh, K., Witsø, E., & Otterlei, M. (2021). Novel Peptides Targeting the β-Clamp Rapidly Kill Planktonic and Biofilm . Frontiers in microbiology, 12631557. https://doi.org/10.3389/fmicb.2021.631557
Raeder, Synnøve Brandt, et al. "Novel Peptides Targeting the β-Clamp Rapidly Kill Planktonic and Biofilm ." Frontiers in microbiology vol. 12 (2021): 631557. doi: https://doi.org/10.3389/fmicb.2021.631557
Raeder SB, Sandbakken ET, Nepal A, Løseth K, Bergh K, Witsø E, Otterlei M. Novel Peptides Targeting the β-Clamp Rapidly Kill Planktonic and Biofilm . Front Microbiol. 2021 Mar 17;12:631557. doi: 10.3389/fmicb.2021.631557. eCollection 2021. PMID: 33815313; PMCID: PMC8009970.
Copy Download .nbib Format: NLM
Changes in cellular signaling proteins in extracts from A549, H460, and U2OS cells treated with cisplatin or docetaxel.

Data in brief

Petrovic V, Olaisen C, Sharma A, Nepal A, Bugge S, Sundby E, Hoff BH, Slupphaug G, Otterlei M.
PMID: 28367485
Data Brief. 2017 Mar 18;12:18-21. doi: 10.1016/j.dib.2017.03.023. eCollection 2017 Jun.

Cell extracts from A549, H460, and U2OS human cancer cell lines treated with cisplatin and docetaxel were analyzed by mass spectrometry (MS) proteomic analysis. The extracts were enriched for cellular signaling proteins using a mix of three different immobilized...

Cite
Petrovic V, Olaisen C, Sharma A, et al. Changes in cellular signaling proteins in extracts from A549, H460, and U2OS cells treated with cisplatin or docetaxel. Data Brief. 2017;12:18-21doi: 10.1016/j.dib.2017.03.023.
Petrovic, V., Olaisen, C., Sharma, A., Nepal, A., Bugge, S., Sundby, E., Hoff, B. H., Slupphaug, G., & Otterlei, M. (2017). Changes in cellular signaling proteins in extracts from A549, H460, and U2OS cells treated with cisplatin or docetaxel. Data in brief, 1218-21. https://doi.org/10.1016/j.dib.2017.03.023
Petrovic, Voin, et al. "Changes in cellular signaling proteins in extracts from A549, H460, and U2OS cells treated with cisplatin or docetaxel." Data in brief vol. 12 (2017): 18-21. doi: https://doi.org/10.1016/j.dib.2017.03.023
Petrovic V, Olaisen C, Sharma A, Nepal A, Bugge S, Sundby E, Hoff BH, Slupphaug G, Otterlei M. Changes in cellular signaling proteins in extracts from A549, H460, and U2OS cells treated with cisplatin or docetaxel. Data Brief. 2017 Mar 18;12:18-21. doi: 10.1016/j.dib.2017.03.023. eCollection 2017 Jun. PMID: 28367485; PMCID: PMC5362150.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 13 entries